Anti-rheumatic compound aurothioglucose inhibits tumor necrosis factor-α-induced HIV-1 replication in latently infected OM10.1 and Ach2 cells

International Immunology

Volumn 11, Issue 2, 1999, Pages 143-150

  Traber, Katrina E ^a   Okamoto, Hiroshi ^a   Kurono, Chieko ^a   Baba, Masanori ^b   Saliou, Claude ^a,c   Soji, Tsuyoshi ^a   Packer, Lester ^c   Okamoto, Takashi ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; Antiviral; NF B; Rheumatoid arthritis; Viral latency

Indexed keywords

ANTIRHEUMATIC AGENT; AUROTHIOGLUCOSE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; DRUG EFFICACY; ELECTRON MICROSCOPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LATENT VIRUS INFECTION; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION;

ANTI-HIV AGENTS; AUROTHIOGLUCOSE; CELL LINE; CHLORAMPHENICOL O-ACETYLTRANSFERASE; GLUTATHIONE; GOLD COMPOUNDS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; MICROSCOPY, ELECTRON; MONOCYTES; NF-KAPPA B; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; VIRUS LATENCY; VIRUS REPLICATION;

EID: 0033043911     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/11.2.143     Document Type: Article

References (37)

1. Baeuerle, P. A. and Baichwal, V. R. 1997. NF-κB as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv. Immunol. 65:111.
2. Baldwin, A. S. 1996. The NF-κB and lκB proteins: new discoveries and insights. Annu. Rev. Immunol. 14:649.
3. Thanos, D. and Maniatis, T. 1995. NF-κB: a lesson in family values. Cell 80:529.
4. Okamoto, T., Sakurada, S., Yang, J.-P. and Merin, J. P. 1997. Regulation of NF-κB and disease control: identification of a novel serine kinase and thioredoxin as effectors for signal transduction pathway for NF-κB activation. Curr. Topics Cell. Reg. 35:149.
5. Hayashi, T., Ueno, Y. and Okamoto, T. 1993. Oxidoreductive regulation of nuclear factor kappa B. J. Biol. Chem. 268:11380.
6. Okamoto, T., Josephs, S. F., Sadaie, M. R. and Wong-Staal, F. 1990. Transcriptional activation from the long-terminal repeat of human immunodeficiency virus in vitro. Virology 177:606.
7. Baeuerle, P. A. and Baltimore, D. 1988. l-kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 242:540.
8. Ghosh, S. and Baltimore, D. 1990. Activation in vitro of NF-kappa B by phosphorylation of its inhibitor l-kappa B. Nature 344:678.
9. Arya, S. R., Guo, C., Josephs, S. F. and Wong-Staal, F. 1985. Trans-activator gene of human lymphotropic virus type III (HTLVIII). Science 229:74.
10. Okamoto, T. and Wong-Staal, F. 1986. Demonstration of virus-specific transcriptional activator(s) in cells infected with HTLV-III by an in vitro cell-free system. Cell 47:29.
11. Okamoto, T., Matsuyama, T., Mori, S., Manamoto, Y., Kobayashi, N., Yamamoto, N., Josephs, S. F., Wong-Staal, F. and Shimotohno, K. 1989. Augmentation of human immunodeficiency virus type 1 gene expression by tumor necrosis factor alpha. AIDS Res. Hum Retroviruses 5:131.
12. Bohnlein, E, Lowenthal, J. W., Siekevitz, M., Ballard, D. W., Franza, B. R. and Greene, W. C. 1988. The same inducible nuclear proteins regulates mitogen activation of both the interleukin-2 receptor-alpha gene and type 1 HIV. Cell 53:827.
13. Madhok, R., Crilly, A., Murphy, E., Smith, J., Watson, J. and Capell, H. A, 1993. Gold therapy lowers serum interleukin levels in rheumatoid arthritis. J. Rheumatol. 20:630.
14. Crilly, A., Madhok, R., Watson, J., Capell, H. A. and Sturrock, R. D. 1994. Production of interleukin-6 by monocytes isolated from rheumatoid arthritis patients receiving second-line drug therapy Br. J. Rheumatol. 33:821.
15. Yanni, G., Nabil, M., Farahat, M. R., Poston, R. N. and Panayi, G. S. 1994. Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane. Ann. Rheum. Dis. 53:315.
16. Loetscher, P., Dewald, B., Baggiolini, M. and Seitz, M. 1994. Monocyte chemoattractant protein 1 and interleukin 8 production by rheumatoid synoviocytes. Effects of anti-rheumatic drugs. Cytokine 6:162.
17. Seitz, M, Dewald, B., Ceska, M., Gerber, N. and Baggiolini, M. 1992. Interleukin-8 in inflammatory rheumatic diseases: synovial fluid levels, relation to rheumatoid factors, production by mononuclear cells, and effects of gold sodium thiomalate and methotrexate. Rheumatol. Int. 12:159.
18. Yoshida, S., Kato, T., Sakurada, S., Kurono, C., Yang, J.-P., Matsui, N., Soji, T. and Okamoto, T. 1999. Inhibition of IL-6 and IL-8 induction from primary rheumatoid synovial fibroblasts by treatment with aurothioglucose. Int. Immunol. 11:151.
19. Williams, D. H., Jeffery, L. J. and Murray, E. J. 1992. Aurothioglucose inhibits induced NF-κB and AP-1 activity by acting as an IL-1 functional antagonist. Biochim. Biophys. Acta 1180:9.
20. Yang, J.-P., Merin, J. P., Nakano, T., Kato, T., Kitade, S. and Okamoto, T. 1995. Inhibition of the DNA-binding activity of NF-κB by gold compounds in vitro. FEBS Lett. 361:89.
21. + cell model of chronic infection. J. Virol. 65:4645.
22. Folks, T. M., Clouse, K. A., Justement, J., Rabson, A., Duh, E., Kehrl, J. H. and Fauci, A. S. 1986. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc. Natl Acad. Sci. USA 86:2365.
23. Luo, Y., Madore, S. J., Parslow, T. G., Cullen, B. R. and Peterlin, B. M. 1993. Functional analysis of interactions between Tat and the trans-activation response element of human immunodeficiency virus 1 in cells. J. Virol. 67:5617.
24. Okamoto, T., Ogiwara, H., Hayashi, T., Mitsui, A., Kawabe, T. and Yodoi, J. 1992. Human thioredoxin/adult T cell leukemia-derived factor activates the enhancer binding protein of human immunodeficiency virus type 1 by thiol redox control mechanism. Int. Immunol. 4:811.
25. Vandeputte, C., Guizon, I., Genestie-Denis, I., Vannier, B. and Lorenzon, G. 1994. A microtiter plate assay for total glutathione and glutathione disulfide contents in cultures/isolated cells: performance study of a new miniaturized protocol. Cell Biol. Toxicol. 10:415.
26. Gallagher, E., Kavanagh, T. and Eaton, D. 1994. Glutathione, oxidized glutathione and mixed disulfides in biological samples. Methods Toxicol. 1B:349.
27. Okamoto, K. and Utamura, M. 1938. Biologische untersuchungen des Goldes. 1 Mitteilung uber die histochemische Gold nachweismethode. Acta Scholae. Med. Kioto. 22:373.
28. Luft, J. 1961. Improvement in epoxy resin embedding methods. J. Biophys. Biochem. Cytol. 9:409.
29. Mascarenhas, B., Granda, J. and Freyberg, R. 1972. Gold metabolism in patients with rheumatoid arthritis treated with gold compounds - reinvestigated. Arthritis Rheum. 15:391.
30. Merin, J. P., Matsuyama, M., Kira, T., Baba, M. and Okamoto, T. 1996. Alpha-lipoic acid blocks HIV-1 LTR-dependent expression of hygromycin resistance in THP-1 stable transformants. FEBS Lett. 394:9.
31. Shapiro, D. L. and Masci, J. R. 1996. Treatment of HIV associated psoriatic arthritis with oral gold. J. Rheumatol. 23:1818.
32. Jacque, J. M., Fernandez, B., Arenzana-Seisdedos, F., Thomas, D,. Baleux, F., Virelizier, J. L. and Bachelerie, F. 1996. Permanent occupancy of the human immunodeficiency virus type 1 enhancer by NF-kB is needed for persistent viral replication in monocytes. J. Virol. 70:2930.
33. Sato, T., Asamitsu, K., Yang, J.-P., Takahashi, N., Tetsuka, T., Yoneyama, A., Kanagawa, A. and Okamoto, T. 1998. Inhibition of HIV-1 replication by fasudil hydrochloride. AIDS Res. Hum. Retroviruses 14:293.
34. Vint, I. A., Foreman, J. C. and Chain, B. M. 1994. The gold anti-rheumatic drug auranofin governs T cell activation by enhancing oxygen free radical production. Eur. J. Immunol. 24:1961.
35. Tozawa, K., Sakurada, S., Kohri, K. and Okamoto, T. 1995. Effects of anti-nuclear factor κB reagents in blocking adhesion of human cancer cells to vascular endothelial cells. Cancer Res. 55:4162.
36. Sakurada, S., Kato, T. and Okamoto, T. 1996. Induction of cytokines and ICAM-1 by proinflammatory cytokines in primary rheumatoid synovial fibroblasts and inhibition by N-acetyl-L-cysteine and aspirin. Int. Immunol. 8:1483.
37. 2- dependence, and differential half-site recognition. J. Biol. Chem. 266:252.